Imatinib for treating patients with chronic myelogeneous leukemia

  • Protocol
  • Intervention

Authors


Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the clinical effectiveness and safety of imatinib as front-line therapy for patients with chronic myeloid leukemia (CML), including those with chronic, accelerated and blastic phases of the disease.